10x Genomics has launched a multi-year research partnership with Dana-Farber Cancer Institute to perform high-resolution single-cell and spatial profiling on tumor specimens from several major solid tumor types, including lung, breast and colorectal cancers. The initial phase will analyze samples from more than 500 patients receiving antibody-drug conjugates, radioligand therapies, bispecific antibodies and immune checkpoint inhibitors, with the goal of correlating cellular composition, spatial architecture and molecular signatures with clinical outcomes and response trajectories.

Investigators will deploy 10x’s Chromium Flex single-cell assay alongside the Xenium spatial platform to generate integrated molecular maps that capture both gene expression at single-cell resolution and spatial context within the tumor microenvironment. By pairing these detailed profiles with anonymized patient histories, treatment regimens and progression metrics, the study aims to uncover resistance mechanisms, identify immune contexture patterns predictive of response, and prioritize biomarkers for inclusion in future diagnostic reports.

To transition research discoveries into potential clinical tests, 10x Genomics plans to build a CLIA-certified laboratory on its Pleasanton campus. This facility will support assay implementation, rigorous analytical validation and processing of clinical samples under regulatory standards. The lab’s infrastructure is designed to accommodate scalable diagnostic workflows, positioning 10x to develop and commercialize next-generation tumor profiling tests that inform precision oncology decision-making.